Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

JNJ-26990990

Copy Product Info
🥰Excellent
Catalog No. T27673Cas No. 877316-38-6

JNJ-26990990 is a broad-spectrum anticonvulsant drug and a second-generation follow-up to the marketed drug topiramate. It offers the same anticonvulsant effects as topiramate but without the side effects associated with topiramate's carbonic anhydrase inhibition. Additionally, JNJ-26990990 has potential use in treating inflammatory pain, neuropathic pain, and depression. [It] entered phase II clinical trials in October 2007.

JNJ-26990990

JNJ-26990990

Copy Product Info
🥰Excellent
Purity: 97.37%
Catalog No. T27673Cas No. 877316-38-6
JNJ-26990990 is a broad-spectrum anticonvulsant drug and a second-generation follow-up to the marketed drug topiramate. It offers the same anticonvulsant effects as topiramate but without the side effects associated with topiramate's carbonic anhydrase inhibition. Additionally, JNJ-26990990 has potential use in treating inflammatory pain, neuropathic pain, and depression. [It] entered phase II clinical trials in October 2007.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$80In StockIn Stock
5 mg$181In StockIn Stock
10 mg$268In StockIn Stock
25 mg$443In StockIn Stock
50 mg$592In StockIn Stock
100 mg$828In StockIn Stock
1 mL x 10 mM (in DMSO)$165In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:97.37%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

JNJ-26990990 AI Summary
JNJ-26990990 is a bioactive agent with diverse pharmacological properties. It demonstrates inhibition of human carbonic anhydrase 2 with IC50 values of 110,000.0 nM and 66,000.0 nM in different assay methods. It also exhibits anticonvulsant activity in various seizure models in mice and rats, with effective doses (ED50) ranging from 21.0 mg/kg to 161.0 mg/kg, and exhibits neurotoxicity in mice and rats, with a TD50 of 182.0 mg/kg in mice and >500.0 mg/kg in rats. Additionally, JNJ-26990990 inhibits rat sodium and calcium channels and shows moderate inhibitory effects on NMDA and kainate receptors in mouse cortical neurons, as well as low-potency activation of GABA receptors in these neurons. The compound reveals antiviral activity by inhibiting SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 μM concentration after 48 hours (inhibition of 30.92%), though its inhibition of SARS-CoV-2 3CL-Pro protease is modest at 15.85% at 20 μM concentration. It demonstrates minimal inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at similar concentrations, with an IC50 value greater than 20,000.0 nM. JNJ-26990990 exhibits a 4.78% inhibition on human HDAC6 with a commercial peptide substrate, but a -5.64% inhibition with a custom peptide substrate, indicating possible selectivity towards different substrates. It displays metabolic stability in liver microsomes and plasma across species, with good bioavailability in mice and rats (F values ranging from 59.0% to 96.0%) and favorable pharmacokinetic properties in terms of clearance, half-life, volume of distribution, and plasma concentrations in these animals..
Note: Summary generated by AI. Data source: ChEMBL
Bioactivity
Description
JNJ-26990990 is a broad-spectrum anticonvulsant drug and a second-generation follow-up to the marketed drug topiramate. It offers the same anticonvulsant effects as topiramate but without the side effects associated with topiramate's carbonic anhydrase inhibition. Additionally, JNJ-26990990 has potential use in treating inflammatory pain, neuropathic pain, and depression. [It] entered phase II clinical trials in October 2007.
Chemical Properties
Molecular Weight242.32
FormulaC9H10N2O2S2
Cas No.877316-38-6
SmilesC(NS(N)(=O)=O)C=1C=2C(SC1)=CC=CC2
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 65 mg/mL (268.24 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM4.1268 mL20.6339 mL41.2677 mL206.3387 mL
5 mM0.8254 mL4.1268 mL8.2535 mL41.2677 mL
10 mM0.4127 mL2.0634 mL4.1268 mL20.6339 mL
20 mM0.2063 mL1.0317 mL2.0634 mL10.3169 mL
50 mM0.0825 mL0.4127 mL0.8254 mL4.1268 mL
100 mM0.0413 mL0.2063 mL0.4127 mL2.0634 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy JNJ-26990990 | purchase JNJ-26990990 | JNJ-26990990 cost | order JNJ-26990990 | JNJ-26990990 chemical structure | JNJ-26990990 formula | JNJ-26990990 molecular weight